rozanolixizumab sold brand name rystiggo monoclonal antibody used treatment myasthenia rozanolixizumab humanized chimeric monoclonal neonatal fc receptor common adverse reactions include headache infections diarrhea pyrexia hypersensitivity reactions rozanolixizumab approved medical use united states june rozanolixizumab indicated treatment generalized myasthenia gravis adults antiacetylcholine receptor antimusclespecific tyrosine kinase antibody rozanolixizumab international nonproprietary november committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product rystiggo intended treatment myasthenia applicant medicinal product ucb immune activation dostarlimab ibalizumab pharmacologyrelated article stub help wikipedia expanding httpsenwikipediaorgwikirozanolixizumab